Here's part of the press release and a link to the rest:
BERKELEY, Calif. (BW HealthWire) - XOMA Ltd. (NASDAQ:XOMA) today announced its financial results for the second quarter of 1999. The Company's net loss for the quarter ended June 30, 1999, was $12.4 million ($0.24 per share) compared to $14.2 million ($0.34 per share) for the quarter ended June 30, 1998. The 1999 year-to-date net loss was $26.0 million ($0.52 per share), compared with $ 24.5 million ($0.61 per share) for the first six months of 1998.
"The past few months have been particularly eventful," said Jack Castello, Chairman, President and CEO of XOMA. "After concluding accrual in the meningococcemia trial in May, we have made a preliminary analysis and are scheduling a meeting with the FDA to present data prior to filing a BLA. We have also concluded several other important business transactions that collectively strengthen the Company's financial position and improve our risk profile. These include expanding our hu1124 relationship with Genentech, signing our first BPI product development partnership with Allergan and, most recently, closing a $17.4 million equity financing with new institutional investors."
Clinical Progress: NEUPREX(R)
NEUPREX(R) is the first product XOMA is developing from its BPI (bactericidal/permeability-increasing protein) drug development platform. The BPI molecule is a human protein with multiple anti-infective properties, a natural part of the body's host-defense system against microbial infection.
-- The Company is in the process of analyzing data from the Phase III pivotal trial of the product in severe meningococcemia. Because this is a rare and life-threatening systemic infection that primarily affects children, the trial was conducted under Subpart E designation, and the indication has received Orphan Drug status. Based on its preliminary analysis XOMA believes the data show a clinical benefit in mortality and morbidities, but is scheduling a meeting with the FDA to determine adequacy for filing a BLA.[my emphasis] The Company is completing the full data analysis in preparation for that meeting.
news.excite.com |
